Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation.

× No keyword cloud information.

25 in total

Review 1. Including adverse drug events in economic evaluations of anti-tumour necrosis factor-α drugs for adult rheumatoid arthritis: a systematic review of economic decision analytic models.

Authors: Eleanor M Heather; Katherine Payne; Mark Harrison; Deborah P M Symmons
Journal: Pharmacoeconomics Date: 2014-02 Impact factor: 4.981

2. Anti-tumour necrosis factor alpha therapy: can we afford it?

Authors: D P M Symmons
Journal: Ann Rheum Dis Date: 2005-07 Impact factor: 19.103

Review 3. TNF-blocking therapy in rheumatoid arthritis and ankylosing spondylitis: why is cost-effectiveness a major issue?

Authors: Sonja Merkesdal; Henning Zeidler
Journal: Curr Rheumatol Rep Date: 2005-08 Impact factor: 4.592

4. Continuous time simulation and discretized models for cost-effectiveness analysis.

Authors: Marta O Soares; Luísa Canto E Castro
Journal: Pharmacoeconomics Date: 2012-12-01 Impact factor: 4.981

Review 5. How to select the right cost-effectiveness model? : A systematic review and stepwise approach for selecting a transferable health economic evaluation model for rheumatoid arthritis.

Authors: H G M van Haalen; J L Severens; A Tran-Duy; A Boonen
Journal: Pharmacoeconomics Date: 2014-05 Impact factor: 4.981

6. The case of tumour necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis: a budget impact analysis.

Authors: Jan Sørensen; Lis S Andersen
Journal: Pharmacoeconomics Date: 2005 Impact factor: 4.981

Review 7. Cellular senescence in ageing: from mechanisms to therapeutic opportunities.

Authors: Raffaella Di Micco; Valery Krizhanovsky; Darren Baker; Fabrizio d'Adda di Fagagna
Journal: Nat Rev Mol Cell Biol Date: 2020-12-16 Impact factor: 94.444

Review 8. Senescent cells: an emerging target for diseases of ageing.

Authors: Bennett G Childs; Martina Gluscevic; Darren J Baker; Remi-Martin Laberge; Dan Marquess; Jamie Dananberg; Jan M van Deursen
Journal: Nat Rev Drug Discov Date: 2017-07-21 Impact factor: 84.694

Review 9. Limits of add-on trials: antirheumatic drugs.

Authors: Laura Ottolenghi; Vittorio Bertele'; Silvio Garattini
Journal: Eur J Clin Pharmacol Date: 2008-09-03 Impact factor: 2.953

Review 10. Economic evaluations in rheumatoid arthritis: a critical review of measures used to define health States.

Authors: Nick Bansback; Roberta Ara; Jonathan Karnon; Aslam Anis
Journal: Pharmacoeconomics Date: 2008 Impact factor: 4.981